Predict your next investment

Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
noblelifesci.com

See what CB Insights has to offer

Stage

Seed - II | Alive

Total Raised

$330K

Last Raised

$100K | 8 yrs ago

About Noble Life Sciences

Noble Life Sciences provides a continuum of preclinical research services, including a best-in-class vivarium, preclinical experimental design and testing, cellular- and animal-based disease models, and a process for the selection and validation of biomarkers, to support therapeutic and diagnostic discoveries for personalized medicine.

Noble Life Sciences Headquarter Location

22 Firstfield Road Suite 280

Gaithersburg, Maryland, 20878,

United States

301-861-0009

Latest Noble Life Sciences News

Noble Life Sciences announces its collaboration with George Mason University to access the National Center for Biodefense and Infectious Diseases BSL-3 facility

Dec 21, 2020

Noble Life Sciences announces its collaboration with George Mason University to access the National Center for Biodefense and Infectious Diseases BSL-3 facility Monday, December 21, 2020 Sykesville, MD, and Fairfax, VA, December 21, 2020 - Noble Life Sciences (NLS), a preclinical contract research organization located in Sykesville, MD, has signed a Collaboration Agreement with George Mason University (Mason) to access the National Center for Biodefense and Infectious Diseases (NCBID) BSL-3 facility located within their Biomedical Research Laboratory at Mason’s Science and Technology Campus in Manassas. The Agreement enables NLS to perform federal and non-federally funded BSL-3 animal model projects to support the development of new antiviral and antibacterial agents against infectious and resistant pathogens. Additionally, NLS and Mason have agreed to explore collaborative research opportunities in the following areas Development of animal models for viral diseases. Development of animal tissue-based and cell culture-based assay methodologies for the assessment of the efficacy of vaccines and therapeutics for viral agents. Assay and reagent development for quantification of viral RNA and/or protein. “Access to the BSL-3 facility through this collaboration agreement with Mason will enable NLS to provide preclinical testing services in support of an immediate need for the development of coronavirus vaccines and therapeutics as well as other emerging infectious diseases,” said Srujana Cherukuri, Chief Executive Officer at NLS “The collaboration with Noble Life Sciences opens doors to new opportunities for the development of novel therapeutics and diagnostics by Mason scientists and enables us to partner with an entity that has extensive experience bringing such new discoveries to the marketplace,” said Ali Andalibi, Chief Scientific Officer of the BRL and Senior Associate Dean in Mason’s College of Science  About Noble Life Sciences: NLS is a preclinical contract research organization (CRO) owned and operated by scientists with decades of experience in drug, vaccine, and medical device development. The company provides integrated GLP and non-GLP preclinical services designed to accelerate development of vaccines and therapeutics in the areas of cancer and infectious diseases. NLS offers services in pharmacology, disease models, early safety assessments, toxicology, PCR, Flow Cytometry, in vivo imaging, and cell-based assays. Learn more at  www.noblelifesci.com About George Mason University: Mason is an educational institution and agency of the Commonwealth of Virginia. Mason’s Biomedical Research Laboratory’s state-of-the-art biocontainment laboratory leverages the tools of molecular biology proteomics and nanotechnology for the development of diagnostics, therapeutics, and vaccines for emerging and potential biothreat agents. The facility is fully approved and licensed for work by the Center for Disease Control and Prevention (CDC), the U.S. Department of Agriculture (USDA), and fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Learn more at ncbid.gmu.edu

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Noble Life Sciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Noble Life Sciences Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.